Mycophenolate mofetil – as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience
- 31 March 2007
- journal article
- case report
- Published by Elsevier BV in Journal of Clinical Neuroscience
- Vol. 14 (3), 278-281
- https://doi.org/10.1016/j.jocn.2005.12.008
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetilNeurology, 2005
- Severe Skin Reaction Related to Mycophenolate Mofetil for Myasthenia GravisClinical Neuropharmacology, 2005
- Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot StudyAnnals of the New York Academy of Sciences, 2003
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Retrospective analysis of the use of cyclosporine in myasthenia gravisNeurology, 2000
- Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetilNeurology, 1998
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995
- Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravisNeurology, 1988